Progenics Pharmaceuticals (PGNX) Shares are Up 1.33%

Progenics Pharmaceuticals (PGNX) has been under a strong bear grip, hence the stock is down -8.71% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.79% in the past 1 week. The stock has risen by 1.33% in the past week indicating that the buyers are active at lower levels, but the stock is down -10.56% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 4.72% and the 50-Day Moving Average is 0.3%.The 200 Day SMA reached 17.89% Progenics Pharmaceuticals, Inc. is up 32.03% in the last 3-month period. Year-to-Date the stock performance stands at -0.49%.


Progenics Pharmaceuticals (PGNX) : The highest level Progenics Pharmaceuticals (PGNX) is projected to reach is $14 for the short term and the lowest estimate is at $9. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $11.5 and the possibility the share price can swing is $3.54.

For this week, the average consensus of the company shares are rated as a Strong Buy. Progenics Pharmaceuticals (NASDAQ:PGNX): stock was range-bound between the intraday low of $6.04 and the intraday high of $6.22 after having opened at $6.21 on Fridays session. The stock finally closed in the red at $6.21, a loss of -1.93%. The stock remained in the red for the whole trading day. The total traded volume was 1,453,147 shares. The stock failed to cross $6.22 in Fridays trading. The stocks closing price on Thursday was $6.1.

Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.